Effects of oral and transdermal estradiol administration on levels of sex hormone-binding globulin in postmenopausal women with and without a history of intrahepatic cholestasis of pregnancy

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 6, 2005, Pages 3431-3434

  Ropponen, A ^a   Aittomaki K ^a   Vihma, V ^a   Tikkanen, M J ^a   Ylikorkala, O ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; SEX HORMONE BINDING GLOBULIN;

ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; INTRAHEPATIC CHOLESTASIS; NORMAL HUMAN; PEPTIDE SYNTHESIS; POSTMENOPAUSE; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ANAMNESIS; BLOOD; COMPARATIVE STUDY; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; PREGNANCY COMPLICATION; REFERENCE VALUE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; CHOLESTASIS, INTRAHEPATIC; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HUMANS; MEDICAL HISTORY TAKING; POSTMENOPAUSE; PREGNANCY; PREGNANCY COMPLICATIONS; REFERENCE VALUES; SEX HORMONE-BINDING GLOBULIN;

EID: 21244476469     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-0352     Document Type: Article

References (20)

1. Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA 1991 Sex hormonebinding globulin: anatomy and physiology of a new regulatory system. J Steroid Biochem Mol Biol 40:813-820
2. Samsioe G 2002 The role of ERT/HRT. Best Pract Res Clin Obstet Gynaecol 16:371-381
3. Pugeat M, Moulin P, Cousin P, Fimbel S, Nicolas MH, Crave JC, Lejeune H 1995 Interrelations between sex hormone-binding globulin (SHBG), plasma lipoproteins and cardiovascular risk. J Steroid Biochem Mol Biol 53:567-572
4. Hogeveen KN, Cousin P, Pugeat M, Dewailly D, Soudan B, Hammond GL 2002 Human sex hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction. J Clin Invest 109:973-981
5. Hogeveen KN, Talikka M, Hammond GL 2001 Human sex hormone-binding globulin promoter activity is influenced by a (TAAAA)n repeat element within an Alu sequence. J Biol Chem 276:36383-36390
6. Jänne M, Hammond GL 1998 Hepatocyte nuclear factor-4 controls transcription from a TATA-less human sex hormone-binding globulin gene promoter. J Biol Chem 273:34105-34114
7. SarrelPM2002 Androgen deficiency: menopause and estrogen related factors. Fertil Steril 77:S63-67
8. Serin IS, Ozcelik B, Basbug M, Aygen E, Kula M, Erez R 2001 Long-term effects of continuous oral and transdermal estrogen replacement therapy on sex hormone binding globulin and free testosterone levels. Eur J Obstet Gynecol Reprod Biol 99:222-225
9. Kramer GR, Kramer RR, Ogden BW, Kilpatrick RE, Gimpel TL, Castracane VD 2003 Variability of serum estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the effect on androgens and sex hormone binding globulin. Fertil Steril 79:534-542
10. Lammert F, Marschall HU, Glantz A, Matern S 2000 Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J Hepatol 33:1012-1021
11. Jacquemin E 2001 Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin Liver Dis 21:551-562
12. Savander M, Ropponen A, Avela K, Weerasekera N, Cormand B, Hirvioja ML, Riikonen S, Ylikorkala O, Lehesjoki AE, Willamson C, Aittomaki K 2003 Genetic evidence of heterogeneity in intrahepatic cholestasis of pregnancy. Gut 52:1025-1029
13. Drill VA 1973 Benign cholestatic jaundice of pregnancy and benign cholestatic jaundice from oral contraceptives. Am J Obstet Gynecol 119:165-174
14. Ropponen A, Aittomäki K, Tikkanen M, Ylikorkala O 2005 Levels of serum C-reactive protein during oral and transdermal estradiol in postmenopausal women with and without a history of intrahepatic cholestasis of pregnancy. J Clin Endocrinol Metab 90:142-146
15. Altman DY, Machin D 2002 Statistics with confidence. 2nd ed. London: BMJ Books
16. Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA 1998 Androgens, estrogens, and second messengers. Steroids 63:278-281
17. Hajamor S, Despres JP, Couillard C, Lemieux S, Tremblay A, Prud'homme D, Tchernof A 2003 Relationship between sex hormone-binding globulin levels and features of the metabolic syndrome. Metabolism 52:724-730
18. Golden SH, Maguire A, Ding J, Crouse JR, Cauley JA, Zacur H, SzkloM2002 Endogenous postmenopausal hormones and carotid atherosclerosis: a casecontrol study of the atherosclerosis risk in communities cohort. Am J Epidemiol 155:437-444
19. Mikkola T, Clarkson T, Notelowitz M 2004 Postmenopausal hormone therapy before and after the women's health initiative study: what consequences? Ann Med 36:402-413
20. Naftolin F, Taylor HS, Karas R, Brinton E, Newman I, Clarkson TB, Mendelsohn M, Lobo RA, Judelson DR, Nachtigall LE, Heward CB, Hecht H, Jaff MR, Harman SM 2004 The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 81:1498-1501